Concepedia
Statistics
Publications
8
Citations
200
H-Index
Active since
2010
Affiliations
The University of Texas MD Anderson Cancer Center(Current)
Cornell University
NewYork–Presbyterian Hospital
Daiichi Sankyo (United States)
New York Hospital Queens
Oleg Zernovak is an author at The University of Texas MD Anderson Cancer Center specializing in oncology, pharmacology, and molecular oncology.
Publications per year
2010–2021
A phase 1 study of MDM2 inhibitor DS-3032b in patients with well/de-differentiated liposarcoma (WD/DD LPS), solid tumors (ST) and lymphomas (L).
Todd M. Bauer, Mrinal M. Gounder, Amy Weise et al. · Journal of Clinical Oncology · 2018 · 44 citations
Medicine, Oncology, Pharmacology +17
Phase 1 Dose Escalation Study of MDM2 Inhibitor DS-3032b in Patients with Hematological Malignancies - Preliminary Results
Courtney D. DiNardo, Joseph Rosenthal, Michael Andreeff et al. · Blood · 2016 · 37 citations
Medicine, Hematology, Oncology +11
Combined inhibition of MDM2 and BCR-ABL1 tyrosine kinase targets chronic myeloid leukemia stem/progenitor cells in a murine model
Bing Z. Carter, Po Yee Mak, Hong Mu et al. · Haematologica · 2019 · 27 citations · Full text
A phase 1 study of the MDM2 inhibitor DS-3032b in patients (pts) with advanced solid tumors and lymphomas.
Mrinal M. Gounder, Todd M. Bauer, Gary K. Schwartz et al. · Journal of Clinical Oncology · 2016 · 23 citations
Preliminary Results of Balli-01: A Phase I Study of UCART22 (allogeneic engineered T-cells expressing anti-CD22 Chimeric Antigen Receptor) in Adult Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Nitin Jain, Gail J. Roboz, Marina Konopleva et al. · Blood · 2020 · 23 citations
Life Sciences, Hematology, Immunology +17
1–5 of 8